We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

39 hedge funds and large institutions have $9M invested in Hepion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

368% more call options, than puts

Call options by funds: $538K | Put options by funds: $115K

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

5% more funds holding

Funds holding: 37 → 39 (+2)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

25% less capital invested

Capital invested by funds: $11.9M → $9M (-$2.93M)

Holders
39
Holders Change
+2
Holders Change %
+5.41%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
10
Closed
7
Calls
$538K
Puts
$115K
Net Calls
+$423K
Net Calls Change
-$697K

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$94.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$68.5K
3
VF
Virtu Financial
New York
+$68.5K
4
AC
Aristides Capital
Kentucky
+$67.1K
5
PAM
PVG Asset Management
Colorado
+$65.7K

Top Sellers

Rank Fund Capital Flow
1
AMC
Asset Management Corp
Illinois
-$204K
2
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$76K
3
HF
HRT Financial
New York
-$53K
4
UBS Group
UBS Group
Switzerland
-$52K
5
PFS
Prospera Financial Services
Texas
-$46K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$26K +$8.22K +6 +35%
SM
27
Sabby Management
Florida
$23K +$27.4K +20 New
GCP
28
GSA Capital Partners
United Kingdom
$23K +$28.8K +21 New
JWM
29
JGP Wealth Management
Oregon
$18K – – –
CSS
30
Cubist Systematic Strategies
Connecticut
$18K +$21.9K +16 New
UBS Group
31
UBS Group
Switzerland
$12K -$52K -38 -79%
AWA
32
Amplius Wealth Advisors
Pennsylvania
$11K +$13.7K +10 New
Commonwealth Equity Services
33
Commonwealth Equity Services
Massachusetts
$11K +$13.7K +10 New
BFEC
34
Benjamin F. Edwards & Company
Missouri
$5K -$2.74K -2 -29%
GWM
35
Geneos Wealth Management
Colorado
$5K – – –
FDCDDQ
36
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.99K – – –
MIFH
37
Migdal Insurance & Financial Holdings
Israel
$2K -$1.37K -1 -33%
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
$1K – – –
US Bancorp
39
US Bancorp
Minnesota
$1K – – –
Wells Fargo
40
Wells Fargo
California
$1K – – –
AMC
41
Asset Management Corp
Illinois
– -$204K -134 Closed
SFI
42
Susquehanna Fundamental Investments
Pennsylvania
– -$76K -50 Closed
HF
43
HRT Financial
New York
– -$53K -35 Closed
PFS
44
Prospera Financial Services
Texas
– -$46K -30 Closed
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
– -$25K -16 Closed
QP
46
Quilter Plc
United Kingdom
– -$17K -11 Closed
FPCP
47
Fort Point Capital Partners
California
– -$15K -10 Closed
1
2

HEPA Hedge Fund Activity: Q4 2021 in Review

39 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2021, worth a combined $9M — down 25% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new HEPA positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $94.5K. The largest seller was Asset Management Corp, exiting entirely with an estimated $204K sold.

  • 39 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $9M of Hepion Pharmaceuticals stock for Q4 2021, down 25% quarter-over-quarter.
  • 9 funds opened new Hepion Pharmaceuticals positions in Q4 2021 and 7 closed out, a net change of +2 holders.
  • The largest Hepion Pharmaceuticals buyer in Q4 2021 was Bank of New York Mellon, an estimated $94.5K added.
  • The largest Hepion Pharmaceuticals seller in Q4 2021 was Asset Management Corp, an estimated $204K sold.

Based on aggregated 13F filings for Q4 2021.